Literature DB >> 20379788

Evaluation of limiting brain penetration related to P-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET in mice.

Kazunori Kawamura1, Tomoteru Yamasaki, Fujiko Konno, Joji Yui, Akiko Hatori, Kazuhiko Yanamoto, Hidekatsu Wakizaka, Makoto Takei, Yuichi Kimura, Toshimitsu Fukumura, Ming-Rong Zhang.   

Abstract

PURPOSE: GF120918 has a high inhibitory effect on P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). We developed [(11)C]GF120918 as a positron emission tomography (PET) probe to assess if dual modulation of P-gp and BCRP is useful to evaluate brain penetration. PROCEDURES: PET studies using [(11)C]GF120918 were conducted on P-gp and/or Bcrp knockout mice as well as wild-type mice.
RESULTS: In PET studies, the AUC(brain) ([0-60 min]) and K (1) value in P-gp/Bcrp knockout mice were nine- and 26-fold higher than that in wild-type mice, respectively. These results suggest that brain penetration of [(11)C]GF120918 is related to modulation of P-gp and BCRP and is limited by two transporters working together.
CONCLUSIONS: PET using [(11)C]GF120918 may be useful for evaluating the function of P-gp and BCRP. PET using P-gp/Bcrp knockout mice may be an effective method to understand the overall contributions the functions of P-gp and BCRP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20379788     DOI: 10.1007/s11307-010-0313-1

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  31 in total

1.  Sensitive measurement of positron emitters eluted from HPLC.

Authors:  M Takei; T Kida; K Suzuki
Journal:  Appl Radiat Isot       Date:  2001-08       Impact factor: 1.513

2.  Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET.

Authors:  Andrew J Montgomery; Marie-Claude Asselin; Lars Farde; Paul M Grasby
Journal:  J Cereb Blood Flow Metab       Date:  2006-05-10       Impact factor: 6.200

3.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Authors:  John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2002-04       Impact factor: 6.261

Review 4.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

Authors:  Pauline Breedveld; Jos H Beijnen; Jan H M Schellens
Journal:  Trends Pharmacol Sci       Date:  2005-12-05       Impact factor: 14.819

5.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

6.  P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

Authors:  Nienke A de Vries; Jin Zhao; Emily Kroon; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

Review 7.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).

Authors:  L Austin Doyle; Douglas D Ross
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

8.  Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats.

Authors:  Gert Luurtsema; Robert C Schuit; Rob P Klok; Joost Verbeek; Josée E Leysen; Adriaan A Lammertsma; Albert D Windhorst
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

9.  In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.

Authors:  Kazunori Kawamura; Tomoteru Yamasaki; Joji Yui; Akiko Hatori; Fujiko Konno; Katsushi Kumata; Toshiaki Irie; Toshimitsu Fukumura; Kazutoshi Suzuki; Iwao Kanno; Ming-Rong Zhang
Journal:  Nucl Med Biol       Date:  2009-04       Impact factor: 2.408

10.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Claire Mercier; Fanchon Bourasset; Françoise Roux; Jean-Michel Scherrmann
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

View more
  17 in total

1.  In vivo evaluation of limiting brain penetration of probes for α(2C)-adrenoceptor using small-animal positron emission tomography.

Authors:  Kazunori Kawamura; Megumi Akiyama; Joji Yui; Tomoteru Yamasaki; Akiko Hatori; Katsushi Kumata; Hidekatsu Wakizaka; Makoto Takei; Nobuki Nengaki; Kazuhiko Yanamoto; Toshimitsu Fukumura; Ming-Rong Zhang
Journal:  ACS Chem Neurosci       Date:  2010-06-02       Impact factor: 4.418

2.  A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.

Authors:  Thomas Wanek; Claudia Kuntner; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Michael Sauberer; Severin Mairinger; Sabine Strommer; Volker Wacheck; Wolfgang Löscher; Thomas Erker; Markus Müller; Oliver Langer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-08       Impact factor: 9.236

Review 3.  Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.

Authors:  Aniv Mann; Inessa Semenenko; Michal Meir; Sara Eyal
Journal:  AAPS J       Date:  2015-03-31       Impact factor: 4.009

4.  Membrane Assays to Characterize Interaction of Drugs with ABCB1.

Authors:  Zsolt Fekete; Zsuzsanna Rajnai; Tünde Nagy; Katalin Tauberné Jakab; Anita Kurunczi; Katalin Gémes; Krisztina Herédi-Szabó; Ferenc Fülöp; Gábor K Tóth; Maciej Czerwinski; Greg Loewen; Peter Krajcsi
Journal:  J Membr Biol       Date:  2015-04-30       Impact factor: 1.843

5.  Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.

Authors:  Ramola Sane; Sagar Agarwal; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-05-18       Impact factor: 3.922

Review 6.  Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Authors:  Sagar Agarwal; Anika M S Hartz; William F Elmquist; Björn Bauer
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 7.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

8.  Inhibiting drug efflux transporters improves efficacy of ALS therapeutics.

Authors:  Michael R Jablonski; Shashirekha S Markandaiah; Dena Jacob; Ni J Meng; Ke Li; Victoria Gennaro; Angelo C Lepore; Davide Trotti; Piera Pasinelli
Journal:  Ann Clin Transl Neurol       Date:  2014-11-21       Impact factor: 4.511

9.  Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113.

Authors:  Severin Mairinger; Thomas Wanek; Claudia Kuntner; Yaprak Doenmez; Sabine Strommer; Johann Stanek; Elena Capparelli; Peter Chiba; Markus Müller; Nicola A Colabufo; Oliver Langer
Journal:  Nucl Med Biol       Date:  2012-09-13       Impact factor: 2.408

10.  Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.

Authors:  Ramola Sane; Sagar Agarwal; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2013-02-08       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.